Advertisement

Clinical and Experimental Nephrology

, Volume 23, Issue 10, pp 1250–1256 | Cite as

The association between cardiac valvular calcification and fetuin-A levels in kidney transplant recipients

  • Nizameddin KocaEmail author
  • Alparslan Ersoy
  • Barış Şensoy
  • Emine Kırhan
  • Sümeyye Güllülü
  • Canan Ersoy
  • Melahat Dirican
  • Emre Sarandöl
Original article
  • 115 Downloads

Abstract

Objectives

Low fetuin-A levels in hemodialysis patients can be associated with development of vascular and valvular calcifications. The mechanisms underlying vascular and valvular calcifications are multifactorial. There are a few studies showing the relationship between low fetuin-A levels and valvular calcification after kidney transplantation. We aimed to evaluate the association between serum fetuin-A levels and valvular calcification in kidney transplant recipients.

Methods

The cardiac valvular calcification was assessed by echocardiography in 56 recipients. Patients were divided into two groups as those with (n = 11) and without (n = 45) aortic and/or mitral valve calcification. The extent of valvular calcification was visually assessed according to the standard visual score method: moderately (multiple larger spots) and heavily calcified (extensive thickening and calcification) of all cusps. Serum fetuin-A levels were measured.

Results

The demographic features of both groups were comparable. There was no significant difference between regular physical exercise (63.6% vs. 55.6%), obesity (18.2% vs. 17.8%), abdominal obesity (54.5% vs. 46.7%), smoking (0% vs. 13.3%), hypertension (63.6% vs. 68.9%), left ventricular hypertrophy (45.5% vs. 33.3%) and diabetes mellitus (9.1% vs. 20%) ratios in groups with or without valvular calcification, respectively (p > 0.05). Fetuin-A levels of both groups did not differ. Fetuin-A levels positively correlated with serum creatinine (r 0.326, p = 0.014), and negatively correlated with estimated glomerular filtration rate (r − 0.297, p = 0.026).

Conclusions

We could not find a relationship between serum fetuin-A levels and valvular calcification in kidney recipients. In this population, further studies are needed to assess the role of serum fetuin-A in valvular calcification.

Keywords

Kidney transplantation Valvular calcification Fetuin A 

Notes

Compliance with ethical standards

Conflict of interest

There is no conflict of interest.

Ethical approval

Ethical approval for human and animal rights (with IRB Approval number: 2009-11/77) was obtained.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Efstratiadis G, Koskinas K, Pagourelias E. Coronary calcification in patients with end-stage renal disease: a novel endocrine disorder? Hormones (Athens). 2007;6(2):120–31.CrossRefGoogle Scholar
  2. 2.
    Wang AY. Vascular and other tissue calcification in peritoneal dialysis patients. Perit Dial Int. 2009;29(Suppl 2):S9–S14.PubMedGoogle Scholar
  3. 3.
    Blacher J, et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38(4):938–42.CrossRefPubMedGoogle Scholar
  4. 4.
    Wang AY, et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol. 2003;14(1):159–68.CrossRefPubMedGoogle Scholar
  5. 5.
    Nguyen PT, et al. Coronary artery calcification: a strong predictor of cardiovascular events in renal transplant recipients. Nephrol Dial Transplant. 2010;25(11):3773–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Braun J, et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis. 1996;27(3):394–401.CrossRefPubMedGoogle Scholar
  7. 7.
    Ossareh S. Vascular calcification in chronic kidney disease: mechanisms and clinical implications. Iran J Kidney Dis. 2011;5(5):285–99.PubMedGoogle Scholar
  8. 8.
    Komaba H, Fukagawa M. Fetuin-mineral complex: a new potential biomarker for vascular calcification? Kidney Int. 2009;75(9):874–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Heiss A, et al. Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem. 2003;278(15):13333–411.CrossRefPubMedGoogle Scholar
  10. 10.
    Small A, et al. Biomarkers of calcific aortic valve disease. Arterioscler Thromb Vasc Biol. 2017;37(4):623–32.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Kuro OM. A phosphate-centric paradigm for pathophysiology and therapy of chronic kidney disease. Kidney Int Suppl (2011). 2013;3(5):420–6.CrossRefGoogle Scholar
  12. 12.
    Westenfeld R, et al. Fetuin-A protects against atherosclerotic calcification in CKD. J Am Soc Nephrol. 2009;20(6):1264–74.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res. 2006;99(10):1044–59.CrossRefPubMedGoogle Scholar
  14. 14.
    Reynolds JL, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol. 2004;15(11):2857–67.CrossRefPubMedGoogle Scholar
  15. 15.
    Tintut Y, et al. Monocyte/macrophage regulation of vascular calcification in vitro. Circulation. 2002;105(5):650–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Ix JH, et al. Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul Study. Circulation. 2007;115(19):2533–9.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Wang AY, et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant. 2005;20(8):1676–85.CrossRefPubMedGoogle Scholar
  18. 18.
    Ketteler M, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003;361(9360):827–33.CrossRefPubMedGoogle Scholar
  19. 19.
    van Summeren MJ, et al. Circulating calcification inhibitors and vascular properties in children after renal transplantation. Pediatr Nephrol. 2008;23(6):985–93.CrossRefPubMedGoogle Scholar
  20. 20.
    Marechal C, et al. Serum fetuin-A levels are associated with vascular calcifications and predict cardiovascular events in renal transplant recipients. Clin J Am Soc Nephrol. 2011;6(5):974–85.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Bortnick AE, et al. Association of inflammatory, lipid and mineral markers with cardiac calcification in older adults. Heart. 2016;102(22):1826–34.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Rosenhek R, et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med. 2000;343(9):611–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55(4):613–8.CrossRefPubMedGoogle Scholar
  24. 24.
    WHO (2018) BMI classification. https://apps.who.int/bmi/index.jsp?introPage=intro_3.html. Accessed 20 Mar 2018
  25. 25.
    Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.PubMedGoogle Scholar
  26. 26.
    Levey AS, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Lebreton JP, et al. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Investig. 1979;64(4):1118–29.CrossRefPubMedGoogle Scholar
  28. 28.
    Ferrari G, et al. Validation of plasma biomarkers in degenerative calcific aortic stenosis. J Surg Res. 2010;163(1):12–7.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Rajamannan NM, et al. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update. Circulation. 2011;124(16):1783–91.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Sainger R, et al. Comparison of transesophageal echocardiographic analysis and circulating biomarker expression profile in calcific aortic valve disease. J Heart Valve Dis. 2013;22(2):156–65.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Koos R, et al. Association of fetuin-A levels with the progression of aortic valve calcification in non-dialyzed patients. Eur Heart J. 2009;30(16):2054–61.CrossRefPubMedGoogle Scholar
  32. 32.
    Kocyigit I, et al. Association between cardiac valvular calcification and serum fetuin-A levels in renal transplant recipients. Transplant Proc. 2015;47(5):1398–401.CrossRefPubMedGoogle Scholar
  33. 33.
    Caglar K, et al. Endothelial dysfunction and fetuin A levels before and after kidney transplantation. Transplantation. 2007;83(4):392–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Di Minno A, et al. Could circulating fetuin A be a biomarker of aortic valve stenosis? Int J Cardiol. 2017;249:426–30.CrossRefPubMedGoogle Scholar
  35. 35.
    Stefan N, Häring H-U. Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans. Nat Med. 2013;19(4):394–5.CrossRefPubMedGoogle Scholar
  36. 36.
    Floege J, Ketteler M. Vascular calcification in patients with end-stage renal disease. Nephrol Dial Transplant. 2004;19(Suppl 5):V59–66.CrossRefPubMedGoogle Scholar
  37. 37.
    Block GA, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–18.CrossRefPubMedGoogle Scholar
  38. 38.
    Sasaki N, et al. Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. Nephrol Dial Transplant. 2001;16(3):479–82.CrossRefPubMedGoogle Scholar
  39. 39.
    Laissy J-P, et al. Aortic valve calcification using multislice CT. Imaging Med. 2011;3(3):313–20.CrossRefGoogle Scholar
  40. 40.
    Ossareh S, Marghoob M, Robabeh B. Relationship between Fetuin-A and vascular or valvular calcification in hemodialysis patients. J Clin Nephrol. 2019;3(1):001–11.CrossRefGoogle Scholar
  41. 41.
    Brix JM, et al. Elevated fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. J Clin Endocrinol Metab. 2010;95(11):4877–81.CrossRefPubMedGoogle Scholar
  42. 42.
    Liabeuf S, et al. Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario? Nephrol Dial Transplant. 2014;29(7):1275–84.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2019

Authors and Affiliations

  1. 1.Department of Internal Medicine, University of Health SciencesBursa Yuksek Ihtisas Training and Research HospitalBursaTurkey
  2. 2.Department of Nephrology and TransplantationUludag UniversityBursaTurkey
  3. 3.Department of Cardiology, University of Health SciencesBursa Yuksek Ihtisas Training and Research HospitalBursaTurkey
  4. 4.Department of BiochemistryTavsanli State HospitalKutahyaTurkey
  5. 5.Department of CardiologyUludag UniversityBursaTurkey
  6. 6.Department of Endocrinology and MetabolismUludag UniversityBursaTurkey
  7. 7.Department of BiochemistryUludag UniversityBursaTurkey

Personalised recommendations